Literature DB >> 19538203

Cognitive and cerebral hemodynamic impairment in scleroderma patients.

G Giuliodori1, P Fraticelli, M Bartolini, C Cagnetti, R Baruffaldi, M B L Rocchi, L Provinciali, A Gabrielli, M Silvestrini.   

Abstract

BACKGROUND AND PURPOSES: Neurological involvement in systemic sclerosis is unusual despite the possible cerebral localization of vascular lesions. The aim of this study was to evaluate cognitive performances and cerebral vasoreactivity in young scleroderma patients without any signs or symptoms of nervous system involvement.
METHODS: Sixteen scleroderma patients and 16 sex- and age-matched healthy subjects without vascular risk factors were included. A neuropsychological assessment for the evaluation of different areas of cognition was performed. For an assessment of cerebrovascular reactivity (CVR), each subject was submitted to hypercapnia with transcranial Doppler ultrasonography using the Breath-Holding Index (BHI).
RESULTS: Patients had significantly lower adjusted mean levels of performance with respect to controls in the Modified Card Sorting Test (P < 0.001) and in the Trail Making Test Parts A and B (P < 0.001 and P < 0.05 respectively). Regarding CVR, BHI values were significantly lower in patients with respect to controls: 0.82 +/- 0.44 vs. 1.34 +/- 0.18, P < 0.0001.
CONCLUSIONS: These findings show the presence of reduced performances of executive functions in scleroderma patients. The associated alteration of CVR in the absence of other apparent causes of cerebrovascular impairment suggests that cognitive problems may be related to an alteration in cerebral perfusion regulation specifically linked to the disease. Further studies are needed to evaluate whether cognitive changes may be positively influenced by treatments aimed to improve vessels functionality in scleroderma patients.

Entities:  

Mesh:

Year:  2009        PMID: 19538203     DOI: 10.1111/j.1468-1331.2009.02714.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

Review 2.  Pathophysiology of cognitive dysfunction and the role of combined brain/heart magnetic resonance imaging (Review).

Authors:  George Markousis-Mavrogenis; Flora Bacopoulou; Genovefa Kolovou; Maria-Roser Pons; Aikaterini Giannakopoulou; Antigoni Papavasiliou; George D Kitas; George P Chrousos; Sophie I Mavrogeni
Journal:  Exp Ther Med       Date:  2022-07-14       Impact factor: 2.751

3.  Absence of association between nailfold capillary findings and mild cognitive dysfunction in systemic lupus erythematosus.

Authors:  Pamela Munguía-Realpozo; Mario García-Carrasco; Claudia Mendoza-Pinto; María de Lourdes Galaviz-Silva; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Álvaro José Montiel-Jarquín; Luis G Vázquez de Lara; Luis H Silveira
Journal:  Clin Rheumatol       Date:  2022-05-27       Impact factor: 3.650

4.  X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma.

Authors:  C Selmi; C A Feghali-Bostwick; A Lleo; S A Lombardi; M De Santis; F Cavaciocchi; L Zammataro; M M Mitchell; J M Lasalle; T Medsger; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 5.  Acute cerebral vasculopathy in systemic sclerosis.

Authors:  Benoit Faucher; Brigitte Granel; Francois Nicoli
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

6.  Psychiatric symptoms and quality of life in systemic sclerosis.

Authors:  G Mura; Krishna M Bhat; A Pisano; G Licci; Mg Carta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-04-20

Review 7.  Cognitive dysfunction in autoimmune rheumatic diseases.

Authors:  Csaba Oláh; Noa Schwartz; Christopher Denton; Zsófia Kardos; Chaim Putterman; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.